Pieris Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Pieris Pharmaceuticals is de winst gegroeid met een gemiddeld jaarlijks percentage van 5.2%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19.1%. De inkomsten zijn gedaald met een gemiddelde van 11.9% per jaar.
Belangrijke informatie
5.2%
Groei van de winst
16.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | -11.9% |
Rendement op eigen vermogen | -98.1% |
Nettomarge | -1,180.0% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Opbrengsten en kosten
Hoe Pieris Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 1 | -16 | 13 | -36 |
30 Jun 24 | 21 | -24 | 17 | 0 |
31 Mar 24 | 41 | -16 | 17 | 0 |
31 Dec 23 | 43 | -25 | 17 | 0 |
30 Sep 23 | 47 | -28 | 19 | 0 |
30 Jun 23 | 33 | -27 | 16 | 0 |
31 Mar 23 | 17 | -41 | 16 | 0 |
31 Dec 22 | 26 | -33 | 16 | 0 |
30 Sep 22 | 28 | -35 | 16 | 0 |
30 Jun 22 | 27 | -42 | 17 | 0 |
31 Mar 22 | 27 | -47 | 17 | 0 |
31 Dec 21 | 31 | -46 | 17 | 0 |
30 Sep 21 | 25 | -51 | 16 | 0 |
30 Jun 21 | 24 | -48 | 16 | 0 |
31 Mar 21 | 32 | -38 | 16 | 0 |
31 Dec 20 | 29 | -37 | 17 | 0 |
30 Sep 20 | 45 | -26 | 18 | 0 |
30 Jun 20 | 57 | -15 | 18 | 0 |
31 Mar 20 | 51 | -22 | 18 | 0 |
31 Dec 19 | 46 | -28 | 18 | 0 |
30 Sep 19 | 34 | -36 | 19 | 13 |
30 Jun 19 | 27 | -40 | 18 | 24 |
31 Mar 19 | 33 | -28 | 19 | 34 |
31 Dec 18 | 29 | -27 | 18 | 41 |
30 Sep 18 | 42 | -8 | 21 | 33 |
30 Jun 18 | 38 | -8 | 19 | 28 |
31 Mar 18 | 28 | -18 | 18 | 24 |
31 Dec 17 | 25 | -18 | 18 | 22 |
30 Sep 17 | 10 | -32 | 14 | 23 |
30 Jun 17 | 7 | -31 | 13 | 22 |
31 Mar 17 | 6 | -27 | 11 | 21 |
31 Dec 16 | 6 | -23 | 9 | 19 |
30 Sep 16 | 5 | -19 | 9 | 15 |
30 Jun 16 | 5 | -17 | 9 | 13 |
31 Mar 16 | 4 | -15 | 8 | 10 |
31 Dec 15 | 3 | -14 | 9 | 8 |
30 Sep 15 | 4 | -15 | 10 | 7 |
30 Jun 15 | 4 | -13 | 8 | 6 |
31 Mar 15 | 4 | -13 | 9 | 6 |
31 Dec 14 | 5 | -10 | 7 | 5 |
30 Sep 14 | 6 | -5 | 5 | 5 |
31 Dec 13 | 12 | 0 | 3 | 9 |
Kwaliteitswinsten: PIRS is momenteel verliesgevend.
Groeiende winstmarge: PIRS is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PIRS is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 5.2% per jaar verminderd.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van PIRS over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: PIRS is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).
Rendement op eigen vermogen
Hoge ROE: PIRS heeft een negatief Return on Equity ( -98.06% ), omdat het momenteel verliesgevend is.